Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Protalix BioTherapeutics, Inc. | tm205240d1_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Protalix BioTherapeutics, Inc. | tm205240d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Protalix BioTherapeutics, Inc. | tm205240d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Protalix BioTherapeutics, Inc. | tm205240d1_ex31-1.htm |
| EX-4.7 - EXHIBIT 4.7 - Protalix BioTherapeutics, Inc. | tm205240d1_ex4-7.htm |
| 10-K - FORM 10-K - Protalix BioTherapeutics, Inc. | tm205240d1_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-230604) and on Form S-8 (No. 333-148983, No. 333-182677, No. 333-203960 and No. 333-225526) of Protalix BioTherapeutics, Inc. of our report dated March 12, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
| /s/ Kesselman & Kesselman |
| Kesselman & Kesselman |
| Certified Public Accountants (lsr.) |
| A member firm of PricewaterhouseCoopers International Limited |
| Tel-Aviv, Israel |
| March 12, 2020 |